{
  "id": "hypopituitarism",
  "title": "Hypopituitarism",
  "lang": "en",
  "source_lang": "en",
  "summary": "Hypopituitarism is deficient pituitary hormone secretion, causing impaired adrenal, thyroid, reproductive, growth, or water-balance function.",
  "category": "health",
  "subcategory": "diseases",
  "type": "concept",
  "aliases": [
    "Pituitary insufficiency",
    "Pituitary hormone deficiency"
  ],
  "generated_at": "2026-11-05",
  "model": "pro/gpt-6.1-sol",
  "url": "https://aiwiki.page/en/hypopituitarism/",
  "translations": {
    "zh-Hans": {
      "url": "https://aiwiki.page/zh/hypopituitarism/",
      "json": "https://aiwiki.page/zh/hypopituitarism.json"
    }
  },
  "sections": [
    {
      "heading": "",
      "text": "Hypopituitarism is a disorder in which the pituitary gland produces insufficient amounts of one or more of its hormones. It may result from damage to the gland itself, disruption of its connection with the hypothalamus, or abnormalities in the development and regulation of the hypothalamic–pituitary system. Because pituitary hormones control several other endocrine organs, the consequences can include cortisol deficiency, central hypothyroidism, impaired fertility, growth failure, and changes in body composition. Associated deficiency of arginine vasopressin affects water balance but is often classified separately from anterior pituitary failure.\n\nThe condition ranges from an isolated hormone deficiency to extensive loss of pituitary function. Some forms are congenital; others follow tumors, surgery, irradiation, vascular injury, inflammation, or head trauma. Symptoms may develop gradually and resemble common illnesses, whereas abrupt loss of cortisol secretion can produce a life-threatening emergency. Diagnosis therefore depends on interpreting pituitary and target-organ hormones together, using stimulation tests when necessary, and identifying the underlying structural or systemic disease. Treatment combines management of the cause with hormone replacement and long-term surveillance."
    },
    {
      "heading": "Pituitary organization and patterns of deficiency",
      "text": "The pituitary lies within the sella turcica, a bony compartment at the base of the skull, and connects to the hypothalamus through the pituitary stalk. Its anterior and posterior portions have different developmental origins and functions. The anterior pituitary synthesizes adrenocorticotropic hormone, thyroid-stimulating hormone, luteinizing hormone, follicle-stimulating hormone, growth hormone, and prolactin. The posterior pituitary stores and releases vasopressin and oxytocin synthesized in hypothalamic neurons. This distinction explains why anterior hormone failure and impaired water regulation do not always occur together.\n\nAnterior pituitary secretion is controlled largely by hypothalamic releasing or inhibitory signals delivered through the hypophyseal portal circulation. Corticotropin-releasing hormone stimulates adrenocorticotropic hormone, which drives adrenal cortisol production. Thyrotropin-releasing hormone stimulates thyroid-stimulating hormone, which supports thyroid hormone synthesis. Gonadotropin-releasing hormone controls luteinizing hormone and follicle-stimulating hormone, which regulate testicular and ovarian function. Growth hormone secretion is governed partly by growth hormone–releasing hormone and somatostatin, while dopamine normally restrains prolactin secretion.\n\nThese systems operate through feedback loops. A low target-organ hormone concentration should ordinarily provoke increased secretion of its pituitary regulator. In pituitary disease, the regulator may instead be low, apparently normal, or occasionally mildly elevated but biologically inadequate. Consequently, a laboratory result within its population reference interval does not necessarily establish normal pituitary function. A normal thyroid-stimulating hormone concentration, for example, can be inappropriate when circulating free thyroxine is low.\n\nThe term isolated deficiency denotes failure of a single hormonal axis; combined pituitary hormone deficiency denotes failure of two or more. Panhypopituitarism generally describes extensive or complete anterior pituitary failure, although usage varies and does not reliably indicate whether vasopressin secretion is intact. “Secondary” endocrine failure usually refers to pituitary disease, whereas “tertiary” failure refers to hypothalamic disease. In clinical practice, “central” is often used for either location because the biochemical patterns overlap.\n\nWith slowly enlarging lesions, growth hormone and gonadotropin secretion are often affected before thyroid-stimulating hormone and adrenocorticotropic hormone. This is not a fixed sequence: autoimmune inflammation, vascular injury, inherited disorders, and treatment-related damage can produce different patterns. Stalk compression may simultaneously reduce several hormones and raise prolactin by interrupting dopamine delivery. Thus, hypopituitarism does not imply that every pituitary hormone concentration is low."
    },
    {
      "heading": "Acquired causes and mechanisms of injury",
      "text": "Pituitary and nearby tumors are major causes of acquired hypopituitarism. A pituitary adenoma, also termed a pituitary neuroendocrine tumor in contemporary pathological classifications, can compress functioning gland tissue or disrupt its circulation. Large nonfunctioning tumors often become apparent through visual disturbance or hormonal deficiency rather than hormone excess. Hormone-secreting tumors can also cause deficiencies in other axes. Craniopharyngiomas, meningiomas, germinomas, and other lesions near the stalk or hypothalamus may impair both anterior pituitary function and water regulation.\n\nTreatment itself can alter pituitary function. Transsphenoidal neurosurgery may restore secretion by relieving compression, but it can also damage functioning tissue. Radiation therapy to the pituitary, hypothalamus, or adjacent brain can cause deficiencies that emerge progressively over years. The probability and timing depend on the radiation dose, treated volume, age, and pre-existing damage. A normal assessment shortly after treatment therefore does not exclude later hormone loss.\n\nVascular injury can be abrupt. Pituitary apoplexy is hemorrhage or infarction, usually within a pituitary tumor, and may cause severe headache, visual impairment, and acute cortisol deficiency. Sheehan syndrome results from ischemic pituitary injury associated with severe obstetric hemorrhage and circulatory compromise. Enlargement of the pituitary during pregnancy contributes to its vulnerability. Failure to lactate and failure of menstruation to resume may precede recognition of broader deficiencies, sometimes by years.\n\nInflammatory disease is another important mechanism. Hypophysitis may be lymphocytic, granulomatous, associated with immunoglobulin G4–related disease, or induced by medication. Lymphocytic hypophysitis has a recognized association with late pregnancy and the postpartum period, although it also occurs outside those settings. Sarcoidosis, Langerhans cell histiocytosis, iron overload, and infections such as tuberculosis can affect the gland, stalk, or hypothalamus. Infiltrative and stalk disorders are particularly important when anterior deficiencies coexist with vasopressin deficiency.\n\nModern cancer treatment has introduced another cause. An immune checkpoint inhibitor can provoke pituitary inflammation or isolated adrenocorticotropic hormone deficiency. The pattern differs among drug classes: cytotoxic T-lymphocyte–associated protein 4 inhibition more often produces recognizable hypophysitis with multiple deficiencies, whereas programmed cell death protein 1 or ligand inhibition may present predominantly as cortisol deficiency without marked gland enlargement.\n\nTraumatic brain injury and subarachnoid hemorrhage can damage the hypothalamic–pituitary system, although reported frequencies vary greatly with case selection and testing methods. Prolonged glucocorticoid exposure can also suppress the hypothalamic–pituitary–adrenal axis. This functional suppression is distinct from destructive pituitary disease but can produce a similar central cortisol-deficiency state after treatment is reduced or withdrawn."
    },
    {
      "heading": "Congenital and genetic forms",
      "text": "Congenital hypopituitarism arises from abnormalities in pituitary development, hormone synthesis, or hypothalamic regulation. It can occur alone or with craniofacial, eye, and other brain abnormalities. The clinical phenotype ranges from isolated growth hormone deficiency to multiple deficiencies apparent soon after birth. Some affected children have a small anterior pituitary, an absent or thin stalk, or an ectopic posterior pituitary located near the hypothalamus rather than within the sella. These findings constitute characteristic components of pituitary stalk interruption syndrome.\n\nPituitary development depends on a sequence of transcription factors that determine the formation and differentiation of hormone-producing cells. Pathogenic variants in PROP1 can cause combined deficiency involving growth hormone, thyroid-stimulating hormone, gonadotropins, and prolactin, with adrenocorticotropic hormone deficiency sometimes developing later. POU1F1 variants characteristically affect growth hormone, prolactin, and thyroid-stimulating hormone secretion. These patterns demonstrate why a molecular defect can selectively disrupt several cell lineages without eliminating all pituitary function.\n\nOther developmental genes link pituitary failure to abnormalities beyond the gland. HESX1, SOX2, SOX3, LHX3, and LHX4 are among the genes associated with variable combinations of endocrine and structural findings. Some LHX3-related disorders include restricted neck movement and hearing impairment. SOX2-related disease may include severe ocular abnormalities. The relationship between genotype and phenotype is not absolute: individuals with the same affected gene may have different hormone deficits, and a recognizable syndrome may occur without an identified molecular cause.\n\nSepto-optic dysplasia illustrates the overlap between endocrine and neurodevelopmental disease. It is defined clinically through combinations of optic nerve hypoplasia, pituitary hormone abnormalities, and midline brain defects, including absence of the septum pellucidum. Not every affected individual has all components. Hormone deficiencies may evolve, so an initially limited endocrine abnormality does not establish that the remaining axes will remain normal.\n\nIn newborns, combined cortisol and growth hormone deficiency may cause recurrent hypoglycemia, while central thyroid hormone deficiency can contribute to prolonged jaundice. In boys, micropenis and undescended testes may indicate gonadotropin deficiency during fetal life and early infancy. Later presentations include reduced linear growth, delayed bone maturation, absent or incomplete puberty, and infertility.\n\nGenetic evaluation is most informative when interpreted alongside the hormone pattern, imaging, family history, and associated physical findings. Familial recurrence, consanguinity, or multiple developmental abnormalities can increase the likelihood of a monogenic cause. Many congenital cases nevertheless remain genetically unexplained. Moreover, a developmental diagnosis does not imply that the hormonal phenotype is static: some deficiencies become apparent only when childhood growth, puberty, or physiological stress places greater demands on the system."
    },
    {
      "heading": "Clinical manifestations across hormonal axes",
      "text": "Symptoms reflect the particular hormones lost, the speed of onset, the age of the affected person, and the underlying lesion. Slowly progressive disease commonly produces nonspecific complaints such as fatigue, reduced exercise tolerance, weakness, and diminished well-being. These features can overlap with chronic illness, sleep disorders, anemia, and depression. A pituitary mass may independently cause headache, loss of peripheral vision, or cranial nerve dysfunction; these are effects of the lesion rather than direct consequences of hormone deficiency.\n\nAdrenocorticotropic hormone deficiency reduces cortisol secretion and produces central adrenal insufficiency. Manifestations include weakness, poor appetite, nausea, weight loss, low blood pressure, and reduced tolerance of physiological stress. Hyponatremia can result because cortisol deficiency promotes vasopressin secretion and impairs free-water excretion. Unlike primary adrenal failure, central disease usually preserves aldosterone secretion, which is regulated mainly through the renin–angiotensin system and potassium. Hyperkalemia and marked salt wasting are therefore less characteristic, and the hyperpigmentation associated with high adrenocorticotropic hormone concentrations is generally absent.\n\nCentral hypothyroidism can cause cold intolerance, constipation, dry skin, slowed cognition, bradycardia, and reduced energy. Symptoms may be subtle when the deficiency is partial. Gonadotropin deficiency produces low sex-steroid concentrations and impaired reproductive function. In premenopausal women, it may cause infrequent or absent menstruation, infertility, vaginal dryness, and reduced sexual desire. In men, manifestations include reduced libido, erectile dysfunction, impaired sperm production, reduced muscle mass, and diminished facial or body hair. In both sexes, prolonged sex-steroid deficiency contributes to bone loss.\n\nGrowth hormone deficiency has strongly age-dependent effects. In children, it primarily impairs linear growth, although neonatal hypoglycemia can be an early manifestation. In adults, it is associated with increased fat mass, reduced lean mass, lower exercise capacity, adverse lipid profiles, and impaired quality of life in some patients. These findings are not specific enough to establish the diagnosis without appropriate biochemical evidence.\n\nProlactin deficiency is most clearly expressed as failure of milk production after childbirth. Outside lactation, its clinical consequences are less well defined, and isolated prolactin deficiency is uncommon. Conversely, a stalk lesion may raise prolactin and thereby further suppress reproductive function.\n\nAssociated arginine vasopressin deficiency, traditionally called central diabetes insipidus, causes large volumes of dilute urine and compensatory thirst. It is distinct from diabetes mellitus. If thirst is intact and water is available, blood sodium may remain normal; impaired thirst or inability to obtain water can lead to severe dehydration and hypernatremia. Cortisol deficiency can partially mask excessive urination, which may become evident after glucocorticoid replacement restores water excretion."
    },
    {
      "heading": "Basal biochemical assessment and differential diagnosis",
      "text": "Diagnosis requires evidence that hormone secretion is inadequate for the physiological circumstances. The medical history establishes whether there has been a sellar tumor, cranial irradiation, head injury, postpartum hemorrhage, relevant medication exposure, or a congenital disorder. Examination can identify impaired growth, delayed puberty, visual-field abnormalities, reduced secondary sexual characteristics, or signs of associated systemic disease. Because individual symptoms have low specificity, laboratory interpretation is central.\n\nAssessment commonly pairs pituitary hormones with the hormones of their target glands. A low free thyroxine concentration with a low or inappropriately normal thyroid-stimulating hormone concentration supports central hypothyroidism in the appropriate setting. Thyroid-stimulating hormone alone is unsuitable both for excluding this diagnosis and for monitoring established central hypothyroidism. Severe nonthyroidal illness, assay interference, and drugs that alter thyroid function can produce overlapping patterns, so biochemical context matters.\n\nCortisol is usually measured in the early morning because secretion follows a circadian rhythm. Very low concentrations strongly support adrenal insufficiency, whereas sufficiently high concentrations make clinically important deficiency less likely. Intermediate results often require dynamic testing. Numerical thresholds depend on the assay and clinical setting; newer cortisol assays may yield lower values than older methods. Oral estrogen, pregnancy, low albumin, and altered cortisol-binding globulin can change total cortisol concentrations without equivalent changes in biologically available hormone.\n\nReproductive-axis testing depends on age and reproductive status. In men, repeated morning testosterone measurements interpreted with luteinizing hormone and follicle-stimulating hormone help distinguish central from primary gonadal failure. In women with menstrual disturbance, estradiol and gonadotropins are interpreted alongside pregnancy status, menstrual history, and other causes of amenorrhea. After natural menopause, gonadotropins should normally be elevated; unexpectedly low or normal concentrations may therefore provide evidence of central dysfunction even when reproductive symptoms are not informative.\n\nInsulin-like growth factor 1 is a useful marker of growth hormone action, but a normal concentration does not reliably exclude adult growth hormone deficiency. Low values can also occur with malnutrition, liver disease, poorly controlled diabetes, and other systemic conditions. Prolactin measurement helps characterize lactotroph function or stalk disruption but does not by itself establish the integrity of other axes.\n\nThe differential diagnosis includes primary endocrine gland failure, medication-related suppression, severe systemic illness, undernutrition, and functional hypothalamic suppression associated with energy deficit. Acute illness can transiently alter several axes at once. Apparent multiple deficiencies therefore require distinction from persistent structural or developmental disease, and test results obtained during critical illness may need reassessment after recovery."
    },
    {
      "heading": "Dynamic testing, imaging, and determination of cause",
      "text": "Dynamic endocrine tests evaluate the ability of an axis to respond to a controlled stimulus. They are most useful when basal hormone concentrations are inconclusive and when establishing a deficiency would change management. Their interpretation depends on the stimulus, laboratory assay, age, body composition, medications, and clinical circumstances. No single stimulation test establishes the function of every pituitary axis.\n\nThe corticotropin stimulation test measures cortisol after administration of synthetic adrenocorticotropic hormone. It assesses adrenal responsiveness rather than directly measuring hypothalamic or pituitary reserve. In longstanding central cortisol deficiency, reduced trophic stimulation leads to diminished adrenal responsiveness. Soon after pituitary injury, however, the adrenal glands may still respond normally, so the test can be falsely reassuring. Conventional protocols use 250 micrograms of synthetic corticotropin; low-dose protocols also exist but introduce additional preparation and standardization issues.\n\nThe insulin tolerance test induces controlled hypoglycemia to stimulate cortisol and growth hormone secretion. It can assess both axes but requires close supervision and is unsuitable for some people, particularly those with seizure disorders or significant ischemic heart disease. Glucagon stimulation is an alternative for growth hormone assessment in some settings. Macimorelin, an oral growth hormone secretagogue, provides another adult testing option where available. Body mass index materially affects stimulated growth hormone responses, and diagnostic cutoffs are test-specific rather than interchangeable.\n\nStructural investigation usually employs dedicated pituitary magnetic resonance imaging. Thin-section images assess the gland, stalk, hypothalamus, optic chiasm, and adjacent structures; contrast enhancement can improve characterization of many lesions. Imaging may reveal a tumor, hemorrhage, gland enlargement, stalk thickening, congenital malformation, or an empty sella. An empty sella means that cerebrospinal fluid occupies part or most of the sellar space and flattens the gland; it does not by itself establish hormone failure.\n\nVisual-field testing is important when a lesion reaches or compresses the optic chiasm. Investigation for infiltrative, inflammatory, infectious, or genetic disease is guided by the imaging pattern and other clinical findings. Stalk thickening accompanied by vasopressin deficiency, for example, raises a different set of possibilities from an uncomplicated anterior pituitary adenoma. Tissue sampling is reserved for selected circumstances because pituitary or stalk biopsy can itself cause injury and is not necessary for every lesion.\n\nSuspected vasopressin deficiency requires assessment of urine volume, urine concentration, plasma sodium, and plasma osmolality. Specialist protocols may use water deprivation or stimulated copeptin measurement; copeptin is a stable marker released alongside vasopressin. These tests distinguish vasopressin deficiency from excessive water intake and renal resistance to vasopressin, disorders that can otherwise produce similar polyuria."
    },
    {
      "heading": "Hormone replacement and treatment of the underlying lesion",
      "text": "Treatment has two related but distinct objectives: managing the causative disease and replacing deficient hormones. Tumor surgery, radiotherapy, treatment of infection, or management of inflammatory disease may preserve remaining function or sometimes allow recovery. Structural treatment does not guarantee endocrine recovery, however, and some interventions create additional deficiencies. Hormonal reassessment is therefore part of follow-up rather than a one-time consequence of diagnosis.\n\nCortisol deficiency is treated with a glucocorticoid, commonly hydrocortisone, in a schedule intended to approximate normal daily secretion. Conventional oral treatment does not fully reproduce physiological pulses or the early-morning cortisol rise. Both underreplacement and overreplacement have consequences: insufficient exposure leaves vulnerability to adrenal crisis, while chronic excess promotes weight gain, metabolic complications, and bone loss. Unlike primary adrenal insufficiency, central disease generally does not require mineralocorticoid replacement because aldosterone secretion is usually preserved.\n\nCentral hypothyroidism is treated with levothyroxine. Free thyroxine, rather than thyroid-stimulating hormone, guides biochemical monitoring because pituitary feedback is abnormal. The sequence of replacement matters: introducing thyroid hormone in someone with untreated cortisol deficiency can precipitate adrenal decompensation by increasing metabolic demand and cortisol clearance. Clinical protocols therefore address adrenal sufficiency before or alongside thyroid replacement.\n\nGonadal hormone replacement depends on age, sex, symptoms, contraindications, and reproductive objectives. Testosterone can restore androgen exposure in men with central hypogonadism but does not restore sperm production and may suppress it further. Fertility treatment instead uses gonadotropins, or pulsatile gonadotropin-releasing hormone when the defect is hypothalamic and pituitary responsiveness is preserved. In women, estrogen replacement, usually combined with a progestogen when the uterus is present, addresses sex-steroid deficiency; ovulation induction requires a separate fertility-oriented approach.\n\nRecombinant growth hormone is used for established growth hormone deficiency in selected children and adults. Pediatric treatment aims principally to support growth, while adult treatment targets documented metabolic, body-composition, skeletal, or quality-of-life consequences. Dosing is individualized using clinical response and age-adjusted insulin-like growth factor 1 concentrations. Fluid retention, joint discomfort, and changes in glucose regulation are recognized adverse effects. Active malignancy is a contraindication.\n\nDesmopressin replaces the antidiuretic action missing in vasopressin deficiency. Its principal treatment-related hazard is excessive water retention and hyponatremia. There is no routine replacement treatment for isolated prolactin deficiency. Interactions between axes complicate management: growth hormone can alter thyroid hormone metabolism and reveal previously borderline central hypothyroidism or cortisol deficiency, while oral estrogen can change replacement requirements through hepatic effects on binding proteins and insulin-like growth factor 1."
    },
    {
      "heading": "Acute emergencies, pregnancy, and life-stage transitions",
      "text": "The principal immediately dangerous endocrine complication is adrenal crisis. In central adrenal insufficiency, infection, surgery, trauma, vomiting, or another major physiological stress can expose an inability to increase cortisol secretion. Features can include hypotension, circulatory shock, severe weakness, nausea, abdominal symptoms, hypoglycemia, and hyponatremia. Hyperkalemia may be absent because aldosterone is usually preserved. Emergency care uses parenteral glucocorticoid and intravenous fluid, with treatment of the precipitating illness. When crisis is strongly suspected, treatment is not delayed for completion of endocrine testing.\n\nPituitary apoplexy combines an acute neurological presentation with possible endocrine collapse. Sudden severe headache, visual loss, double vision, altered consciousness, and acute cortisol deficiency are characteristic possibilities. It can resemble subarachnoid hemorrhage or meningitis. Management involves urgent endocrine, neurological, ophthalmological, and neurosurgical assessment. Some patients undergo decompressive surgery, while others are managed conservatively; the approach depends particularly on visual and neurological findings and their progression.\n\nWater-balance disturbances can be especially complex after pituitary surgery. Early vasopressin deficiency may be followed by an antidiuretic phase as injured nerve terminals release stored hormone, with permanent deficiency developing in a subset. This possible triphasic response explains why urine output and sodium can change in opposite directions over a short period. Delayed postoperative hyponatremia may also occur without a complete triphasic pattern. Desmopressin exposure, intravenous fluids, cortisol status, and thirst all influence the resulting sodium concentration.\n\nDuring pregnancy, normal endocrine physiology changes substantially. Estrogen increases thyroid- and cortisol-binding proteins, the placenta produces hormones that modify maternal endocrine regulation, and the pituitary enlarges. Women with hypopituitarism may require assisted reproduction, and established pregnancies require coordinated assessment of hormone replacement and any underlying sellar lesion. Hydrocortisone is commonly used for cortisol replacement because placental metabolism limits fetal exposure. Thyroid replacement requirements may increase, and thyroid-stimulating hormone remains unreliable as a treatment marker in central disease.\n\nChildhood-to-adult transition presents a different challenge. Growth hormone deficiency diagnosed in childhood may be transient in some patients, particularly in isolated cases without a permanent structural or genetic cause. Reassessment after completion of growth distinguishes persistent deficiency from a diagnosis that no longer applies. Patients with established multiple deficiencies or certain structural abnormalities have a much higher probability of persistence.\n\nAcross these settings, continuity of replacement is a major patient-safety issue. Inability to take oral medication, interruptions during hospitalization, and confusion over which laboratory markers reflect adequate treatment can have disproportionate consequences. Long-term care systems commonly incorporate documented emergency plans, medication reconciliation, and communication between endocrine and other clinical teams."
    },
    {
      "heading": "Epidemiology, historical development, and long-term outcomes",
      "text": "Population estimates of hypopituitarism depend heavily on which deficiencies and causes are included. A population-based study in northwestern Spain, published in 2001, reported a prevalence of approximately 45.5 cases per 100,000 people and an annual incidence of about 4.2 per 100,000. These figures are frequently cited but are not universal estimates: they reflect a particular population, period, and ascertainment method. Studies restricted to treated adults, hospital populations, childhood disorders, or survivors of brain injury describe different clinical groups.\n\nRecognition has changed as survival after pituitary tumors, childhood cancer, and serious brain injury has improved. Long-term survivors of cranial irradiation may develop new hormone deficiencies years after treatment. Conversely, improved obstetric care and control of postpartum hemorrhage have reduced Sheehan syndrome in settings with reliable maternity services. Its continuing occurrence elsewhere illustrates how the distribution of acquired hypopituitarism depends partly on health-system conditions rather than endocrine biology alone. Immune checkpoint inhibitor therapy has added a newer treatment-associated population.\n\nThe modern clinical concept developed through early twentieth-century pathological observations. In 1914, the German physician Morris Simmonds described severe illness associated with destructive pituitary disease, helping establish the syndrome historically called Simmonds disease. In 1937, Harold Leeming Sheehan described postpartum pituitary necrosis and clarified its relationship to severe obstetric hemorrhage. Later development of hormone assays, stimulation testing, computed tomography, and magnetic resonance imaging made it possible to identify partial deficiencies and structural causes before advanced wasting or collapse.\n\nReplacement therapy also changed substantially. Glucocorticoids and thyroid hormone transformed survival and daily functioning, while gonadotropins enabled fertility treatment in selected patients. Growth hormone treatment initially relied on extracts from human pituitaries. Recognition in 1985 of Creutzfeldt–Jakob disease transmission associated with cadaveric pituitary growth hormone led to withdrawal of those preparations; recombinant human growth hormone subsequently removed that particular source of infectious risk.\n\nLong-term outcomes remain heterogeneous. Observational studies have reported increased mortality in some hypopituitary populations, particularly from cardiovascular, cerebrovascular, respiratory, and infectious causes. Interpretation is complicated by the underlying tumor, prior irradiation, age at diagnosis, the extent of hormone loss, and historical replacement practices. These studies do not establish that a single deficiency or replacement regimen accounts for the excess risk.\n\nPersistent effects can include reduced health-related quality of life, impaired work participation, adverse body composition, and osteoporosis. Current research examines more physiological cortisol delivery, long-acting growth hormone formulations, improved diagnostic thresholds, genetic causes, and patient-reported outcomes. Important unresolved questions include how best to detect clinically meaningful dysfunction after brain injury and how to distinguish nonspecific symptoms from consequences that respond to hormone replacement."
    }
  ],
  "links": [
    "hypothalamus",
    "somatostatin",
    "dopamine",
    "neurosurgery",
    "radiation-therapy",
    "tuberculosis",
    "immune-checkpoint-inhibitor",
    "hypoglycemia",
    "fatigue",
    "anemia",
    "hypothyroidism",
    "erectile-dysfunction",
    "diabetes-mellitus",
    "medical-history",
    "circadian-rhythm",
    "menopause",
    "differential-diagnosis",
    "magnetic-resonance-imaging",
    "biopsy",
    "corticosteroid",
    "levothyroxine",
    "pregnancy",
    "patient-safety",
    "prevalence",
    "health-related-quality-of-life",
    "osteoporosis"
  ],
  "sources": [],
  "license": "https://creativecommons.org/licenses/by/4.0/"
}